Literature DB >> 26838522

Lewis-Sumner syndrome associated with infliximab therapy in ulcerative colitis.

Giovanni Cirillo1, Vincenzo Todisco1, Gioacchino Tedeschi2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26838522     DOI: 10.1007/s10072-016-2490-4

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  7 in total

1.  Lewis-Sumner syndrome and multifocal motor neuropathy.

Authors:  Annie Verschueren; Jean Philippe Azulay; Shahram Attarian; José Boucraut; Jean François Pellissier; Jean Pouget
Journal:  Muscle Nerve       Date:  2005-01       Impact factor: 3.217

2.  Lewis and Sumner syndrome following infliximab treatment in Crohn's disease: a report of 2 cases.

Authors:  Stephane Nancey; Françoise Bouhour; Gilles Boschetti; Christophe Magnier; Pierre-Marie Gonneau; Jean-Christophe Souquet; Dominique Kaiserlian; Bernard Flourie
Journal:  Inflamm Bowel Dis       Date:  2010-09       Impact factor: 5.325

3.  Multifocal demyelinating neuropathy with persistent conduction block.

Authors:  R A Lewis; A J Sumner; M J Brown; A K Asbury
Journal:  Neurology       Date:  1982-09       Impact factor: 9.910

Review 4.  Monoclonal antibody therapy-associated neurological disorders.

Authors:  Xavier Bosch; Albert Saiz; Manuel Ramos-Casals
Journal:  Nat Rev Neurol       Date:  2011-01-25       Impact factor: 42.937

Review 5.  Lewis-sumner syndrome of pure upper-limb onset: diagnostic, prognostic, and therapeutic features.

Authors:  Yusuf A Rajabally; Govindsinh Chavada
Journal:  Muscle Nerve       Date:  2009-02       Impact factor: 3.217

6.  Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.

Authors:  Pierre Lozeron; Christian Denier; Catherine Lacroix; David Adams
Journal:  Arch Neurol       Date:  2009-04

Review 7.  Tumor necrosis factor-alpha antagonists and neuropathy.

Authors:  Joerg-Patrick Stübgen
Journal:  Muscle Nerve       Date:  2008-03       Impact factor: 3.217

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.